CGRP Modulating Therapies: An Update

Curr Neurol Neurosci Rep. 2024 Sep;24(9):453-459. doi: 10.1007/s11910-024-01363-w. Epub 2024 Jul 17.

Abstract

Introduction: Calcitonin-gene related peptide (CGRP) is a vasoactive neuropeptide involved in the pathophysiology ofmigraine. CGRP has been targeted for both preventive and acute treatment of migraine.

Objective: Provide a summary of the most clinically relevant literature surrounding CGRP modulating therapies.

Methods: This update on CGRP modulating therapies includes articles selected as most clinically relevant by theauthors.

Conclusion: CGRP modulating therapies are an exciting new addition to migraine treatment given their safety andtolerability. Additionally, compared to traditional migraine preventive medication these treatments are migrainespecific.Further real-world and clinical data is ongoing to better understand these treatments that continue to gainfavor in the management of migraine.

Keywords: Calcitonin gene-related peptide; Calcitonin gene-related peptide monoclonal antibody; Calcitonin gene-related peptide receptor antagonist; Migraine treatment; Migraine without aura.

Publication types

  • Review

MeSH terms

  • Calcitonin Gene-Related Peptide Receptor Antagonists / pharmacology
  • Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use
  • Calcitonin Gene-Related Peptide* / antagonists & inhibitors
  • Calcitonin Gene-Related Peptide* / metabolism
  • Humans
  • Migraine Disorders* / drug therapy
  • Migraine Disorders* / metabolism

Substances

  • Calcitonin Gene-Related Peptide
  • Calcitonin Gene-Related Peptide Receptor Antagonists